TMH CTN is a national resource for the advancement of knowledge and understanding in the fields of transfusion medicine and hemostasis. The network will promote the efficient comparison of new management strategies for individuals with hemostatic disorders and evaluate new and existing blood products and cytokines for treatment of hematologic disorders. Weill Cornell Medical Center/New York Presbyterian Hospital is one of the 17 Core sites in this network. Cornell hopes to help accelerate research of blood products and novel growth factors in the treatment of hemostatic disorders, standardize approaches to existing diagnoses and treatments, evaluate new treatments, emphasize clinical trials to facilitate optimal therapy, and conduct therapeutic trials researching investigational drugs or blood products. In order to accomplish these goals, we are going to conduct clinical trials that are/will be approved to use human subjects by our IRB, the Data Safety and Management Board, the New England Research Institute Steering Committee, and the executive committee. As a core clinical centers in the TMH network, we are responsible for recruiting, examining, and treating study participants;and for collecting all clinical, laboratory, demographic, and other data required by each TMH Network study. We recruit patients by determining their eligibility for a study and obtaining their informed consent. All examinations of patients, treatment of patients, and attainment of patient specimens are conducted by trained medical personnel. Dr. James Bussel, as our site's Primary Investigator, is responsible for ensuring that all aspects of TMH Network protocols are followed.

National Institute of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Research Project--Cooperative Agreements (U01)
Project #
Application #
Study Section
Special Emphasis Panel (ZHL1-CSR-J (M1))
Program Officer
Mondoro, Traci
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Weill Medical College of Cornell University
Schools of Medicine
New York
United States
Zip Code
Bussel, James B; Lee, Christina S; Seery, Caroline et al. (2014) Rituximab and three dexamethasone cycles provide responses similar to splenectomy in women and those with immune thrombocytopenia of less than two years duration. Haematologica 99:1264-71
Ramaswamy, Kavitha; Hsieh, Loan; Leven, Emily et al. (2014) Thrombopoietic agents for the treatment of persistent and chronic immune thrombocytopenia in children. J Pediatr 165:600-5.e4
Psaila, Bethan; Bussel, James B; Linden, Matthew D et al. (2012) In vivo effects of eltrombopag on platelet function in immune thrombocytopenia: no evidence of platelet activation. Blood 119:4066-72
Triulzi, Darrell J; Assmann, Susan F; Strauss, Ronald G et al. (2012) The impact of platelet transfusion characteristics on posttransfusion platelet increments and clinical bleeding in patients with hypoproliferative thrombocytopenia. Blood 119:5553-62
Josephson, Cassandra D; Granger, Suzanne; Assmann, Susan F et al. (2012) Bleeding risks are higher in children versus adults given prophylactic platelet transfusions for treatment-induced hypoproliferative thrombocytopenia. Blood 120:748-60
Psaila, B; Bussel, J B; Frelinger, A L et al. (2011) Differences in platelet function in patients with acute myeloid leukemia and myelodysplasia compared to equally thrombocytopenic patients with immune thrombocytopenia. J Thromb Haemost 9:2302-10
Slichter, Sherrill J; Kaufman, Richard M; Assmann, Susan F et al. (2010) Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med 362:600-13
Steiner, M E; Assmann, S F; Levy, J H et al. (2010) Addressing the question of the effect of RBC storage on clinical outcomes: the Red Cell Storage Duration Study (RECESS) (Section 7). Transfus Apher Sci 43:107-16
Bussel, James B (2009) Traditional and new approaches to the management of immune thrombocytopenia: issues of when and who to treat. Hematol Oncol Clin North Am 23:1329-41
Hasan, Aisha; Michel, Marc; Patel, Vivek et al. (2009) Repeated courses of rituximab in chronic ITP: Three different regimens. Am J Hematol 84:661-5

Showing the most recent 10 out of 14 publications